Key Takeaways

• Vulvar cancer most commonly affects the labia majora and is predominantly diagnosed in postmenopausal women.
• Persistent itching, unusual skin changes, and unexplained lumps on the vulva are among the most important early warning signs.
• Human papillomavirus (HPV) infection and lichen sclerosus are recognized as key risk factors.
• Treatment typically involves surgery, radiation therapy, chemotherapy, or a combination of these approaches.
• When detected at an early stage, the five-year survival rate can exceed 85%, underscoring the value of routine gynecological exams.

Vulvar Cancer Symptoms, Causes, and Risk Factors

Recognizing the vulvar cancer symptoms and early warning signs is essential for timely diagnosis. The most common symptom is persistent itching or burning on the vulva that does not resolve with standard treatments. Other warning signs include unusual skin changes such as thickening, roughening, or discoloration of the vulvar skin, the appearance of a lump, wart-like growth, or open sore, and pain or tenderness in the pelvic region. Some individuals also notice bleeding unrelated to menstruation or unusual discharge. Because these symptoms can mimic benign conditions like dermatitis or yeast infections, many women delay seeking medical advice, which is why any persistent or unexplained change in the vulvar area warrants prompt evaluation by a healthcare provider.

Understanding the vulvar cancer causes and risk factors helps clarify who may be at elevated risk. The development of vulvar cancer is often multifactorial. Infection with certain strains of human papillomavirus (HPV), particularly HPV-16 and HPV-18, is linked to a significant proportion of cases. Chronic inflammatory skin conditions, especially lichen sclerosus, are also associated with an increased likelihood of malignant transformation. Other contributing factors include a history of cervical cancer or cervical intraepithelial neoplasia, a weakened immune system, and long-term cigarette smoking.

Additional risk factors include advancing age, as the condition is most frequently diagnosed in women over 65, and a personal history of vulvar intraepithelial neoplasia (VIN), which is a precancerous condition of the vulvar skin. Obesity and certain sexually transmitted infections beyond HPV may also elevate risk, though their roles are still being studied. It is important to note that having one or more risk factors does not guarantee that cancer will develop; however, individuals with multiple risk factors should discuss screening options with their physician.

Stages of Vulvar Cancer and How It Is Diagnosed

Accurate staging is central to planning effective treatment. The stages of vulvar cancer are defined by the International Federation of Gynecology and Obstetrics (FIGO) system, which classifies the disease based on tumor size, depth of invasion, lymph node involvement, and the presence of distant metastasis. Understanding each stage helps clinicians determine the most appropriate therapeutic strategy and allows patients to have realistic expectations about their prognosis.

Diagnosis of vulvar cancer typically begins with a thorough clinical examination and a detailed patient history. Physicians inspect the vulva for visible abnormalities and may apply dilute acetic acid to highlight suspicious tissue. A colposcopy may be performed to magnify the area for closer inspection. The definitive diagnostic step is a tissue biopsy, in which a small sample of abnormal skin is removed and analyzed by a pathologist. This procedure is straightforward and can usually be performed in an outpatient setting under local anesthesia.

Once a biopsy confirms malignancy, additional imaging studies help establish the full extent of disease. These may include magnetic resonance imaging (MRI) of the pelvis, computed tomography (CT) scans of the abdomen and pelvis, and, in some cases, positron emission tomography (PET) scans to assess for distant spread. Sentinel lymph node biopsy is increasingly used to evaluate regional lymph node involvement with minimal surgical morbidity. Together, these tools allow oncologists to assign an accurate stage and tailor the treatment plan accordingly, which is why learning how to detect vulvar cancer early through regular gynecological exams and self-awareness remains a clinical priority.

Vulvar Cancer Treatment Options and Therapies

The vulvar cancer treatment options and therapies available today are diverse and are selected based on the cancer’s stage, location, the patient’s overall health, and individual preferences. A multidisciplinary team including gynecologic oncologists, radiation oncologists, and medical oncologists typically collaborates to develop a personalized treatment plan. Surgery remains the cornerstone of treatment for most stages of vulvar cancer.

Surgical approaches range from wide local excision, which removes the tumor along with a margin of healthy tissue, to a radical vulvectomy, which removes all or most of the vulva. The choice of procedure depends on the size and location of the tumor. For early-stage disease, conservative surgery that preserves as much normal tissue as possible is preferred to minimize functional and psychological impact. Sentinel lymph node biopsy or inguinofemoral lymphadenectomy is often performed alongside the primary surgery to assess or remove regional lymph nodes.

Radiation therapy is used both as a primary treatment and as an adjunct to surgery. It may be delivered before surgery to shrink a large tumor, after surgery to reduce recurrence risk, or in combination with chemotherapy for advanced disease. Chemotherapy agents such as cisplatin, with or without 5-fluorouracil, are used concurrently with radiation to enhance its effectiveness. Immunotherapy and targeted therapy are emerging areas of research, with checkpoint inhibitors showing promise in clinical trials for recurrent or metastatic cases. Patients should discuss all available options with their care team to make fully informed decisions.

Survival Rate and Long-Term Prognosis

The vulvar cancer survival rate and prognosis are strongly influenced by the stage at which the disease is detected. According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database, the overall five-year relative survival rate for vulvar cancer is approximately 71%. However, this figure varies considerably by stage: localized disease carries a five-year survival rate of around 86%, while cases with regional lymph node involvement drop to approximately 53%, and distant metastatic disease falls below 20%.

Beyond stage, several additional factors affect long-term outcomes. These include the histologic subtype of the tumor, the depth of stromal invasion, the presence or absence of lymphovascular space involvement, and the patient’s immune status. Squamous cell carcinoma accounts for roughly 90% of vulvar cancers, while melanoma, adenocarcinoma, and Bartholin gland carcinoma represent rarer subtypes with distinct prognostic profiles. Younger patients without lymph node involvement and with smaller tumors generally experience more favorable outcomes.

Long-term survivorship care is an important component of management. Survivors may face physical challenges such as lymphedema, sexual dysfunction, urinary changes, or emotional distress related to body image. Regular follow-up appointments are essential for monitoring for recurrence, managing treatment side effects, and supporting overall quality of life. Psychological support, pelvic floor physiotherapy, and patient education programs have all demonstrated benefit in improving well-being after treatment. Early-stage detection through awareness and routine care remains the most effective strategy for achieving the best possible outcomes.